Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...
A live webcast will be available on the Alumis website in the "Investors" section under the “Events” page.
In a report released today, Jeff Jones from Oppenheimer reiterated a Buy rating on Alumis Inc. (ALMS – Research Report), with a price target of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback